February 10, 2020 / 9:57 PM / 10 days ago

BRIEF-Janssen Announces Submission To U.S. FDA For New Darzalex-Based Combination Regimen

Feb 10 (Reuters) - Johnson & Johnson:

* JANSSEN ANNOUNCES SUBMISSION TO U.S. FDA FOR NEW DARZALEX® (DARATUMUMAB)-BASED COMBINATION REGIMEN FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

* JANSSEN ONCOLOGY - SUBMISSION OF SUPPLEMENTAL BLA TO FDA SEEKING APPROVAL OF DARZALEX IN COMBINATION WITH KYPROLIS & DEXAMETHASONE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below